SPIRIT 2: Efficacy and Safety Study of Relugolix in Women With Endometriosis-Associated Pain

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2017
The purpose of this study is to determine the benefit and safety of relugolix 40 milligrams (mg) once daily, co-administered with low-dose estradiol (E2) and norethindrone acetate (NETA) compared with placebo for 24 weeks, on dysmenorrhea and on nonmenstrual pelvic pain.
Epistemonikos ID: af7300fe1974dee8faae720391620699dc04ae74
First added on: May 20, 2024